COMPEDICA LIMITED

• ⚠

  Material uncertainty over going concern

  We draw attention to note 1(a) to the consolidated financial statements which indicates that the Group is reliant on financial support from its parent to continue its clinical trial stage and its ability to provide such support is dependent on further fund raising within the going concern period. As indicated in that note, there is a reasonable possibility that the parent entity may either not be able to provide the necessary funding given the quantum of the amounts involved or would not have a business rationale to provide such support given the uncertainty over the commercial viability of the product. These events and conditions, along with the other matters explained in note 1(a) constitute a material uncertainty that may cast significant doubt on the Group's and the Company's ability to continue as a going concern. Our opinion is not modified in this respect. However, these circumstances indicate the existence of a material uncertainty related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern and, therefore, that the Group may be unable to realise its assets and discharge its liabilities in the normal course of business.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +43.6%

  £6,378 → £9,161

• Cash

  -92.9%

  £342,827 → £24,331

• Net assets

  -241.1%

  £7,773,313 → -£10,965,089

  lowest in 3 filed years

• Employees

  0%

  3 → 3

• Operating profit

  +9.1%

  -£3,477,965 → -£3,161,672

• Profit before tax

  +8.4%

  -£3,485,675 → -£3,191,776

• Wages

  -3.5%

  £278,243 → £268,452

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. COMPEDICA LIMITED 2022-02-08 → present
2. COMPEDICA HOLDINGS LIMITED 2022-02-08 → 2022-02-08
3. DBC MEDICAL LTD 2020-11-12 → 2022-02-08
4. WOLSELEY MANAGERS LIMITED 2020-08-26 → 2020-11-12

Accounting basis

UK-adopted International Accounting standards

Reporting scope

Consolidated group

Auditor

KPMG Audit LLC

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 1(a) to the consolidated financial statements which indicates that the Group is reliant on financial support from its parent to continue its clinical trial stage and its ability to provide such support is dependent on further fund raising within the going concern period. As indicated in that note, there is a reasonable possibility that the parent entity may either not be able to provide the necessary funding given the quantum of the amounts involved or would not have a business rationale to provide such support given the uncertainty over the commercial viability of the product. These events and conditions, along with the other matters explained in note 1(a) constitute a material uncertainty that may cast significant doubt on the Group's and the Company's ability to continue as a going concern. Our opinion is not modified in this respect. However, these circumstances indicate the existence of a material uncertainty related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern and, therefore, that the Group may be unable to realise its assets and discharge its liabilities in the normal course of business.”

Group structure

1. COMPEDICA LIMITED · parent
   1. Compedica Inc 100% · Nevada · Non-Trading Dormant

Significant events

• “In R&D, the Company achieved a key milestone with the delivery of the Generation II Alpha Prototype in December.”
• “On June 30th, 2025, the intercompany loan between the company and Compedica holdings Ltd (The parent company) was converted into equity. The value of that loan at June 30th, 2025, was £10,543,536, an increase from the December 31, 2024, valuation of £811,003, which represents additional funding received during 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.